Insider Transactions in Q4 2023 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2023
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
27,100
-45.46%
|
$1,355,000
$50.19 P/Share
|
|
Dec 28
2023
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
27,100
+31.25%
|
$1,273,700
$47.34 P/Share
|
|
Dec 28
2023
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
11,029
-22.96%
|
$551,450
$50.5 P/Share
|
|
Dec 28
2023
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
11,500
+19.32%
|
$540,500
$47.34 P/Share
|
|
Dec 28
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,798
-36.23%
|
$2,189,900
$50.5 P/Share
|
|
Dec 28
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,225
+27.23%
|
$2,125,575
$47.34 P/Share
|
|
Dec 28
2023
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
42,525
-33.99%
|
$2,126,250
$50.19 P/Share
|
|
Dec 28
2023
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
42,525
+25.37%
|
$1,998,675
$47.34 P/Share
|
|
Dec 27
2023
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
50,000
-37.71%
|
$2,500,000
$50.23 P/Share
|
|
Dec 27
2023
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+27.38%
|
$2,350,000
$47.34 P/Share
|
|
Dec 26
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
25,000
-40.95%
|
$1,275,000
$51.46 P/Share
|
|
Dec 26
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+29.05%
|
$1,175,000
$47.34 P/Share
|
|
Dec 26
2023
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
25,113
-23.32%
|
$1,280,763
$51.46 P/Share
|
|
Dec 26
2023
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,113
+18.91%
|
$1,180,311
$47.34 P/Share
|
|
Dec 26
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
20,825
-34.04%
|
$1,062,075
$51.46 P/Share
|
|
Dec 26
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,825
+25.39%
|
$978,775
$47.34 P/Share
|
|
Dec 21
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,500
-12.9%
|
$857,500
$49.29 P/Share
|
|
Dec 21
2023
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+11.43%
|
$822,500
$47.34 P/Share
|
|
Dec 21
2023
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,112
-5.34%
|
$201,488
$49.29 P/Share
|
|
Dec 21
2023
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,112
+5.07%
|
$193,264
$47.34 P/Share
|
|
Dec 21
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,113
-19.68%
|
$789,537
$49.29 P/Share
|
|
Dec 21
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,113
+16.45%
|
$757,311
$47.34 P/Share
|
|
Dec 20
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,500
-5.22%
|
$318,500
$49.64 P/Share
|
|
Dec 20
2023
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+4.96%
|
$305,500
$47.34 P/Share
|
|
Dec 20
2023
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
6,500
-8.18%
|
$318,500
$49.64 P/Share
|
|
Dec 20
2023
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+7.56%
|
$305,500
$47.34 P/Share
|
|
Dec 20
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,500
-9.0%
|
$318,500
$49.64 P/Share
|
|
Dec 20
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+8.25%
|
$305,500
$47.34 P/Share
|
|
Dec 14
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
22,612
-14.57%
|
$1,107,988
$49.7 P/Share
|
|
Dec 14
2023
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,612
+12.66%
|
$1,062,764
$47.34 P/Share
|
|
Dec 14
2023
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,613
-6.76%
|
$520,037
$49.7 P/Share
|
|
Dec 14
2023
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,613
+6.31%
|
$498,811
$47.34 P/Share
|
|
Dec 14
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,000
-9.18%
|
$1,176,000
$49.7 P/Share
|
|
Dec 14
2023
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+8.38%
|
$1,128,000
$47.34 P/Share
|
|
Nov 15
2023
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Direct |
2,000
-10.9%
|
$100,000
$50.0 P/Share
|
|
Oct 17
2023
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Indirect |
52
-41.6%
|
$2,444
$47.95 P/Share
|
|
Oct 16
2023
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Indirect |
125
+50.0%
|
-
|
|
Oct 12
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,770
-3.09%
|
$173,420
$46.0 P/Share
|